Anemia is not part of the normal aging process and should trigger a workup for myeloid neoplasms.Barzi A, Sekeres MA. Cleve Clin J Med. 2010;77(1):37-44
When left untreated, MDS-related anemia can have a severe impact on quality of life and cause significant morbidity and mortality.Germing U et al. Hemasphere. 2019;3(6):e314.
Early assessment and investigation of the underlying causes of anemia are essential to improve long-term outcomes.Germing U et al. Hemasphere. 2019;3(6):e314.
* This video is sponsored by Bristol Myers Squibb. The speaker has been compensated for his time.
Anemia is a frequent condition in the elderly. The cause of anemia is unexplained in one third of cases, and it may be attributed to myeloid neoplasms.Stauder R. Blood. 2018;131:505-514. Alvarez-Payares JC et al. Cureus. 2021;13:e19971.
MDS should be suspected in elderly patients with isolated, unexplained anemia. About 1 in 6 patients with unexplained anemia has findings compatible with MDS.McDonald L et al. Blood. 2018;132:5515-5515. Hasserjian RP et al. Blood. 2023;142:2247-2257. Foran JM, Shammo JM. Am J Med. 2012;125(suppl):S6-S13.
Prognostic scoring allows assessment of disease severity. Risk stratification is important to understand the disease trajectory and enable a tailored clinical approach.Hasserjian RP et al. Blood. 2023;142:2247-2257. Platzbecker U et al. Leukemia. 2021;35:2182-2198.
MDS-related anemia shortens patients’ length and quality of life. Chronic anemia and transfusion dependence are the main clinical challenges in lower-risk MDS.Platzbecker U et al. Leukemia. 2021;35:2182-2198. Oliva EN et al. Blood Rev. 2021;50:100851.
Diagnosing MDS requires an extensive series of tests, but it is also important to have a high clinical suspicion to identify risk factors for developing MDS, such as advancing age.Hasserjian RP et al. Blood. 2023;142:2247-2257. Sekeres MA. Hematol Oncol Clin North Am. 2010;24:287-294.
The site will assist U.S. healthcare providers in caring for patients and conducting research with BMS medicines.
